

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/550,196
				Filing Date	January 12, 2007
				First Named Inventor	Madeleine M. Joullie
				Art Unit	1654
Examiner Name	CORDERO GARCIA, MARCELA M.				
Sheet	1	of	4	Attorney Docket Number	1694.0610001/JMC/THN

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
	NPL48	Abdel-Magid, A.F., <i>et al.</i> , "Reductive Amination of Aldehydes and Ketones by Using Sodium Tricetoxyborohydride," <i>Tetrahedron Lett.</i> 31:5595-5598, Pergamon Press plc, UK (1990)		
	NPL49	Abdel-Magid, A.F. & Maryanoff, C.A., "Reductive Amination of Aldehydes and Ketones with Weakly Basic Anilines Using Sodium Triacetoxyborohydride," <i>Synlett.</i> 537-539, Germany (1990)		
	NPL50	Ahuja, D., <i>et al.</i> , "Inhibition of Protein Synthesis by Didemnins B: How EF-1 α Mediates Inhibition of Translocation," <i>Biochemistry</i> 39:4339-4346, American Chemical Society, United States (2000)		
	NPL51	Ahuja, D., <i>et al.</i> , "Inhibition of Protein Synthesis by Didemnins: Cell Potency and SAR," <i>J. Med. Chem.</i> 43:4212-4218, American Chemical Society, United States (2000)		
	NPL52	Campbell, M.J., <i>et al.</i> , "Growth inhibition of DU-145 prostate cancer cells by a <i>Bcl-2</i> antisense oligonucleotide is enhanced by <i>N</i> -(2-hydroxyphenyl)all- <i>trans</i> retinamide," <i>Brit. J. of Cancer</i> 77:739-744, Cancer Research Campaign, UK (1998)		
	NPL53	Crews, C.M., <i>et al.</i> , "Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis," <i>Proc. Natl. Acad. Sci. USA</i> 93:4316-4319, Natl. Acad. Sci., United States (1996)		
	NPL54	Ding, X., <i>et al.</i> , "Structure-Activity Relationships of Side-Chain Modified Didemnins," <i>Bioorg. Med. Chem. Lett.</i> 11:231-234, Elsevier Science Ltd., United States (2001)		
	NPL55	Ewing, W.R., <i>et al.</i> , "SYNTHETIC STUDIES OF DIDEMNINS. I. REVISION OF THE STEREOCHEMISTRY OF THE HYDROXYISOVALERYLPROPIONYL (HIP) UNIT," <i>Tetrahedron</i> 42:5863-5868, Pergamon Journals Ltd., UK (1986)		
	NPL56	Ewing, W.R., <i>et al.</i> , "SYNTHETIC STUDIES OF DIDEMNINS. IV. SYNTHESIS OF THE MACROCYCLE," <i>Tetrahedron Lett.</i> 30:3757-3760, Maxwell Pergamon Macmillan plc, UK (1989)		
	NPL57	Harris, B.D., <i>et al.</i> , "SYNTHETIC STUDIES OF DIDEMNINS. II. APPROACHES TO STATINE DIASTEREOMERS," <i>Tetrahedron Lett.</i> 28:2837-2840, Pergamon Journals Ltd., UK (1987)		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/550,196	
				Filing Date	January 12, 2007	
				First Named Inventor	Madeleine M. Joulle	
				Art Unit	1654	
				Examiner Name	CORDERO GARCIA, MARCELA M.	
Sheet	2	of	4	Attorney Docket Number		1694.0610001/JMC/THN

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL58	Harris, B.D., <i>et al.</i> , "SYNTHETIC STUDIES OF DIDEMNINS. III: SYNTHESIS OF STATINE AND ISOSTATINE STEREOISOMERS," <i>Tetrahedron</i> 44:3489-3500, Pergamon Press plc, UK (1988)	
	NPL59	Jou, G., <i>et al.</i> , "Total Synthesis of Dehydrodidemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in Peptide Synthesis in Solution," <i>J. Org. Chem.</i> 62:354-366, American Chemical Society, United States (1997)	
	NPL60	Joullié, M.M., <i>et al.</i> , "Total Synthesis of (-)-tamandarin B," <i>Tetrahedron Lett.</i> 41:9373-9376, Elsevier Science Ltd., UK (2000)	
	NPL61	Joullié, M.M., <i>et al.</i> , "Chemical Defense in Ascidians of the <i>Didemnidae</i> Family," <i>Bioconjugate Chem.</i> 14:30-37, American Chemical Society, United States (2003)	
	NPL62	Li, W.-R. & Joullié, M.M., "The Didemnins: Biological Properties, Chemistry and Total Synthesis," <i>Studies in Natural Products Chemistry</i> , 10:241-302, Elsevier Science Publishers B.V., The Netherlands (1992)	
	NPL63	Mayer, S.C., <i>et al.</i> , "Synthesis of New Didemnin B Analogs for Investigations of Structure/Biological Activity Relationships," <i>J. Org. Chem.</i> , 59:5192-5205, American Chemical Society, United States (1994)	
	NPL64	Mayer, S.C., <i>et al.</i> , "Synthetic Routes to a Constrained Ring Analog of Didemnin B," <i>J. Org. Chem.</i> 61:1655-1664, American Chemical Society, United States (1996)	
	NPL65	Mayer, S.C., <i>et al.</i> , "Synthetic Studies of a Constrained Ring Didemnin Analog," <i>Tetrahedron: Asymmetry</i> 5:519-522, Elsevier Science Ltd., UK (1994)	
	NPL66	Mayer, S.C., <i>et al.</i> , "The Cyclic Dipeptide Backbone of the Didemnins," <i>Acta Cryst. C51</i> :1609-1614, International Union of Crystallography, UK (1995)	
	NPL67	Pfizenmayer, A.J., <i>et al.</i> , "SYNTHESIS AND BIOLOGICAL ACTIVITIES OF [N-MeLeu ⁵] DIDEMNIN B," <i>Biol. Med. Chem. Lett.</i> 6:2713-2716, Elsevier Science Ltd., UK (1996)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/550,196	
				Filing Date	January 12, 2007	
				First Named Inventor	Madeleine M. Joullie	
				Art Unit	1654	
				Examiner Name	CORDERO GARCIA, MARCELA M.	
Sheet	3	of	4	Attorney Docket Number		1694.0610001/JMC/THN

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
	NPL68	Portonovo, P., <i>et al.</i> , "First Total Synthesis of a Fluorescent Didemnin," <i>Tetrahedron</i> 56:3687-3690, Elsevier Science Ltd., UK (2000)		
	NPL69	Ramanjulu, J.M., <i>et al.</i> , "A Facile Synthesis of Benzyl 2-Amino-3-Azido-4-O-p-Methoxybenzyl-6-O-Benzyl-2,3-Dideoxy- α -D-Glucopyranoside: A Key Intermediate in the Formation of a Didemnin B Analog," <i>J. Carbohydrate Chemistry</i> 15:371-381, Marcel Dekker, Inc., United States (1996)		
	NPL70	Ramanjulu, J.M., <i>et al.</i> , "Analogues of the β -Turn of the Cyclodepsipeptide Didemnin B," <i>Tetrahedron Letters</i> 37:311-314, Elsevier Science Ltd., UK (1996)		
	NPL71	Ramanjulu, J.M., <i>et al.</i> , "Syntheses of Acyclic Analogs of Didemnin B," <i>Synthetic Communications</i> 27:3259-3272, Marcel Dekker, Inc., United States (1997)		
	NPL72	Ramanjulu, J.M., <i>et al.</i> , "Synthesis of a Reduced Ring Analog of Didemnin B," <i>J. Org. Chem.</i> 62:4961-4969, American Chemical Society, United States (1997)		
	NPL73	Ramanjulu, J.M., <i>et al.</i> , "Synthetic Studies of a Didemnin B Analog Based on a 2,3-Diamino Sugar Scaffolding," <i>J. Chin. Chem. Soc.</i> 48:1-4, The Chemical Society, Taiwan (2001)		
	NPL74	Schumacher, K.K., <i>et al.</i> , "Synthetic studies toward astins A, B and C. Efficient syntheses of <i>cis</i> -3,4-dihydroxyprolines and (-)-(3 <i>S</i> ,4 <i>R</i>)-dichloroproline esters," <i>Tetrahedron: Asymmetry</i> 9:47-53, Elsevier Science Ltd., UK (1998)		
	NPL75	Tarver Jr., J.E., <i>et al.</i> , "Total Syntheses of Conformationally Constrained Didemnin B Analogues. Replacements of <i>N</i> , <i>O</i> -Dimethyltyrosine with L-1,2,3,4-Tetrahydroisoquinoline and L-1,2,3,4-Tetrahydro-7-methoxyisoquinoline," <i>J. Org. Chem.</i> 66:7575-7587, American Chemical Society, United States (2001)		
	NPL76	Vera, M.D., <i>et al.</i> , "[Lys ³] Didemnins as Potential Affinity Ligands," <i>Biorg. Med. Chem. Lett.</i> 11:13-16, Elsevier Science Ltd., UK (2001)		
	NPL77	Vera, M.D. & Joullié, M.M., "Natural Products as Probes of Cell Biology: 20 Years of Didemnin Research," <i>Medicinal Research Reviews</i> 22:102-145, John Wiley & Sons, Inc., United States (2002)		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/550,196
				Filing Date	January 12, 2007
				First Named Inventor	Madeleine M. Joullie
				Art Unit	1654
				Examiner Name	CORDERO GARCIA, MARCELA M.
Sheet	4	of	4	Attorney Docket Number 1694.0610001/JMC/THN	
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	NPL78	Vera, M.D., <i>et al.</i> , "Synthesis and Biological Evaluation of Didemnin Photoaffinity Analogues," <i>Biorg. Med. Chem. Lett.</i> 11:1871-1874, Elsevier Science Ltd., UK (2001)			
	NPL79	Vervoort, H. & Fenical, W., "Tamandarins A and B: New Cytotoxic Depsipeptides from a Brazilian Ascidian of the Family Didemnidae," <i>J. Org. Chem.</i> 65:782-792, American Chemical Society, United States (2000)			
	NPL80	Wipf, P., "Synthetic Studies of Biologically Active Marine Cyclopeptides," <i>Chem. Rev.</i> 95:2115-2134, American Chemical Society, United States (1995)			
	NPL81	Xiao, D., <i>et al.</i> , "Total Synthesis of a Conformationally Constrained Didemnin B," <i>J. Org. Chem.</i> 66:2734-2742, American Chemical Society, United States (2001)			
	NPL82	STNEasy/CAPLUS English language Abstract of Spanish Patent Publication No. ES 2 102 322 A1 (1997), document FP1, Accession No. 1998:169709			

1125067_1.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Examiner Signature	/Marcela Cordero Garcia/	Date Considered	11/15/2010
--------------------	--------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.